Skip to main content
    H

    Heron Therapeuti (HRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.28
    -0.03 (-8.44%)

    Market Cap: $59.08M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Heron Therapeuti (HRTX) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Heron Therapeuti (HRTX) trades at 0.4x sales and 14.0x book value. Its P/S of 0.4x is below its 5-year median of 2.0x. Its forward P/E is 47.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E47.0x
    Price to sales0.4x
    Price to book14.0x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 95.9% below 9.8x.

    MultipleCurrent5-year median10-year median
    P/S0.4x2.0x9.8x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 119 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 1.4x in 2025 to 402.3x in 2016. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$1.301.4x15.1x
    2024$1.531.6xN/A
    2023$1.701.8xN/A
    2022$2.502.5x21.9x
    2021$9.1310.4x12.0x
    2020$21.1721.7x8.2x
    2019$23.5013.1x5.2x
    2018$25.9424.9x5.5x
    2017$18.1033.3x8.9x
    2016$13.10402.3xN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About HRTX

    What is HRTX's forward P/E ratio?

    Heron Therapeuti has a forward P/E ratio of 47.0x.

    What is HRTX's price to sales ratio?

    Heron Therapeuti has a price to sales ratio of 0.4x.